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We employed differential display of expressed mRNAs
(Liang, P., and Pardee, A. B. (1992) Science 257, 967–971)
to identify genes up-regulated after long term potentia-
tion (LTP) induction in the hippocampus of awake adult
rats. In situ hybridization confirmed the differential ex-
pression of five independently amplified clones repre-
senting two distinct transcripts, cl13/19/90 and cl95/96.
Neither cl13/19/90 nor cl95/96 showed significant se-
quence homology to known transcripts (mRNA or ex-
pressed sequence tag) or to the mouse or human ge-
nome. However, comparison with the rat genome
revealed that they are localized to a predicted intron of
the phosphodiesterase Pde10A gene. cl13/19/90 and
cl95/96 are likely to be part of the Pde10A primary tran-
script as, using reverse transcriptase-PCR, we could
specifically amplify distinct introns of the Pde10A pri-
mary transcript, and in situ hybridization demonstrated
that a subset of Pde10A splice variants are also up-reg-
ulated after LTP induction. These results indicate that
amplification of a primary transcript can faithfully re-
port gene activity and that differential display can be
used to identify differential expression of RNA species
other than mRNA. In transiently transfected Cos7 cells,
Pde10A3 reduces the atrial natriuretic peptide-induced
elevation in cGMP levels without affecting basal cGMP
levels. This cellular function of LTP-associated Pde10A
transcripts argues for a role of the cGMP/cGMP-depend-
ent kinase pathway in long term synaptic plasticity.
Memory, the recollection of acquired information, is encoded
in the brain as enduring changes in distributed neural net-
works. Synapses that support activity-dependent changes in
synaptic efficacy are therefore a likely location of information
storage inthebrain.Longtermpotentiation (LTP)1 isanactivity-
dependent long lasting increase in synaptic efficacy in the
hippocampus and other cortical structures and is the main
cellular model for learning and memory (2). There is strong
evidence indicating that LTP constitutes a neural substrate for
some forms of learning and memory (3): (i) both LTP and
learning depend on the activation of similar signal transduc-
tion cascades (4); (ii) animal models in which the induction of
LTP is impaired are generally also impaired in hippocampal-
dependent learning and memory (see, e.g., Refs. 5–8, but see
Ref. 9); (iii) mice that show enhanced LTP also show en-
hanced learning and memory (10, 11); and (iv) behavioral
paradigms can induce an increase in the synaptic strength in
the amygdala (12).
Another point of congruence is the requirement for de novo
RNA and protein synthesis both for the formation of long term
memory (13, 14) and the late stage of LTP, L-LTP (15–17). The
observation that L-LTP requires de novo RNA and protein
synthesis has led to a search for genes that are modulated by
LTP. To date, several transcripts have been identified and
include both transcription factors (e.g. Zif268) (18–20), as well
as proteins with a cellular and/or synaptic function (20–26). In
addition to de novo RNA and protein synthesis, LTP may also
be associated with the induction of novel splice isoforms (27,
28). Although not all regions of the hippocampal formation
have a similar transcriptional response to electrical stimula-
tion (29, 30), experiments in which expression or function of
LTP-associated transcripts was perturbed has demonstrated
their importance for the expression of (L-)LTP (8, 31–35). More-
over, expression of LTP-modulated transcripts such as Zif268
and Arc/Arg3.1 appears to be both associated with specific
learning tasks (36–39) and required for the formation of long
term memories (8, 33–35). These proteins and their associated
biological functions therefore are beginning to provide an in-
sight into the molecular bases of the long term changes under-
lying synaptic plasticity and memory consolidation.
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In this study we employed differential display of expressed
mRNAs (1) to identify genes induced by LTP in the awake
animal. Although differential display is primarily aimed to
identify changes in expression levels of mRNA, our analysis
highlighted the ability of this technique to identify differential
expression of other RNA species. Using in situ hybridization,
we were able to confirm the differential expression of five
clones that represent two independent transcripts, cl13/19/90
and cl95/96. We provide evidence demonstrating these clones
are part of the primary transcript (i.e. RNA prior to excision of
introns) of Pde10A, a gene encoding a cGMP phosphodiesterase
(40–43). Our results argue for a role of the cGMP/cGMP-de-
pendent kinase (cGK) pathway in long term synaptic plasticity.
EXPERIMENTAL PROCEDURES
In Vivo Recordings—Eighty-five male Sprague-Dawley (Iffa Credo,
France) rats weighing between 300 and 350 g were prepared for chronic
unilateral recording in the dentate gyrus as described previously (44).
Detailed experimental protocols used in this study for the induction
and recording of LTP in the awake rat have been described (25). All
experiments were conducted in accordance with the recommendations
of the EU directive (86/609/EEC) and the French National Committee
(87/848).
Differential Display—Differential display experiments were per-
formed as described (25). The primers that led to the differential am-
plification of cl13/19/90 and cl95/96 were: Cl19, ACGACTCACTATAG-
GGC(T)12CG and ACAATTTCACACAGGACGACTCCAAG; Cl13, ACG-
ACTCACTATAGGGC(T)12CG and ACAATTTCACACAGGACGACTC-
CAAG; Cl90, ACGACTCACTATAGGGC(T)12AG and ACAATTTCACA-
CAGGACGACTCCAAG; Cl95, ACGACTCACTATAGGGC(T)12CA and
ACAATTTCACACAGGACTTTCTACCC; and Cl96, ACGACTCACTAT-
AGGGC(T)12CA and ACAATTTCACACAGGACTTTCTACCC.
Electroconvulsive Shock (ECS)—ECS was induced in 20 rats follow-
ing light halothane anesthesia. Ear-clip electrodes were used to deliver
200 V (sine wave) at 50 mA for 2 s to induce clonic seizure according to
published protocols (74). Animals were subsequently allowed to recover
before being sacrificed 1, 3, 6, 12, or 24 h after ECS (n  4 per group).
Control rats (n  6) were subjected to equivalent handling without
subsequent stimulation. All brains were removed, frozen on dry ice, and
stored at 80 °C prior to subsequent analysis by in situ hybridization.
In Situ Hybridization—Coronal sections (14 m) were mounted on
polylysine-coated Superfrost slides and stored at 80 °C. In situ hy-
bridization was performed essentially as described elsewhere (29).
Briefly, sections were thawed, fixed in 4% paraformaldehyde, acety-
lated in 1.4% triethanolamine and 0.25% acetic anhydride, dehydrated
through graded ethanol solutions, and delipidated in chloroform. Sec-
tions were hybridized overnight at 42 °C in 100 l of buffer containing
50% formamide, 4 SSC, 10% dextran sulfate, 5 Denhardt’s solution,
200 mg/ml acid alkali-cleaved salmon testis DNA, 100 mg/ml long chain
polyadenylic acid, 25 mM sodium phosphate (pH 7.0), 1 mM sodium
pyrophosphate, and 100,000 cpm radiolabeled probe (1 ng/ml) under
parafilm coverslips. Sections were washed in 1 SSC at 55 °C (30 min),
0.1 SSC at room temperature (5 min), and dehydrated in ethanol.
Sections were then exposed to autoradiographic film. [35S]ATP-end-
labeled probes (PerkinElmer Life Sciences) were generated using ter-
minal deoxynucleotidyltransferase (Promega) according to instructions
from the manufacturer. A 50-fold excess of unlabeled oligonucleotide
was used as a negative control; for probes cl13/19/90, cl95/96, cl77, and
WS, labeled sense oligonucleotides served as an additional control.
Antisense sequences were: Cl13/19/90, AGCCATTTCCCAGATGCT-
CGCCCAGTATCTTTGAAAGGGGTCAG; Cl95/96, ATGGCAGAAGGC-
AGGGAAAGCAGGTTGGCAGGAGAAGAAGGCTGA; Cl77, AGCACG-
CACAAAGCATTCTGGGATTTCTGCCTCTGCGGGTCTTGA; WS, TC-
TCTGGCTCAAGACTTGGCAAGACAGGTGGTTCAGGAGAGGTGA;
YB, GAAGCAACTCGCATTGTTAGAGGGTCCATCTTCCATGTCG-
GAG; YC, TCAGGAATGTTCAGGACTTCTCCCGTTCTTGCCACTTG-
ACCAG; YD, GGCTTCCAGTCCATGTGCAGTGGTCCTCTGTAGGCA-
TCCATG; YE, AAACCAGGCAGTGGGTTCCTCCTCTGGGAGCTGGG-
GTTCTC; and YF, CCGCCAAAGTATCCTCCAGTACAAAACT-
CCTTTCTGCTTCATT.
Labeled sections were exposed to high resolution film (Kodak Bi-
omaxMR). Autoradiographs were analyzed by measuring the integrated
density relative to a 14C standard using NIH Image or SAMBA. The
signal intensity in stimulated dentate was expressed as a percentage of
the unstimulated contralateral dentate granule cell layer. ECS acti-
vates gene expression on both sides of the brain; in these experiments,
Pde10A expression was compared with the levels in sham-handled, and
age-matched controls. The statistical significance of any differences
following LTP or ECS treatment as compared with respective controls
was assessed using Student’s t test.
RT-PCR—Total RNA was isolated from adult rat hippocampus, cer-
ebellum, cortex, and olfactory bulb using TRIzol (Invitrogen) according
to instructions from the manufacturer. 10 g of total RNA was treated
with 4 units of DNase for 15 min. at 37 °C. 3 g of DNase-treated RNA
samples were then reverse transcribed for 1 h at 50 °C in the presence
of 200 units of Superscript III (Invitrogen), 150 ng of oligo(dT)18 primer,
0.5 mM dNTPs, 50 mM DTT, and RNase inhibitor in a total volume of 20
l. A control reaction was performed in absence of reverse tran-
scriptase; control samples were otherwise treated identically.
0.2 l from the reverse transcribed cDNA was used for each RT-PCR
reaction. Primer pairs used for detection of the primary transcript were
(from 5 to 3 end of the Pde10A gene): GTGGTTGTGTGACATTTTCC-
ATCC and GACCTTGGGTTTGTGCTGTTTC (primers o-p), ATCCCG-
ACCCTTGGCTTCTCAATG and TGCTTGTCTGCTTTCTTCCCTG, TT-
GCTCCCTGGTGCTGTTTG and TCCTCCATTGCTCTCAGAAGCC,
GGTTCGTTTGCTGTTGGCTTAG and TATTACACCCATCCCGCT-
CCTC (primers m-n), GGATAGACCTAAGGCAACCACAAG and TCA-
CAATGGCTTCTGACACGC, AGGATGCAGTCCATGATGGTGG and
ACTTAAACCCTTGGTCTCTGCTAGG (within cl95/96), TGAAGCCCC-
AGCACTACACAACTC and CCATTCTTTCTCCCTCCAGACATAC
(primers k-l), TTCTCAGCCATCTTCTCCCACC and TCTGCCTTTTTT-
CTCCCTTTGG, GGGGATAATAGCTCAAGGGAGACC and AGCACA-
GAATCCAGAAGAGGGTATC (primers i-j), TATGCGAAAGCACCAG-
TCGG and TTCTCTTCACACAGTAGCACCCTG, TGGAATGGCATCG-
GCTTGTAGC and TGGTCCTCATAATCCTGTGTCTGC (primers g-h),
ACTGAGGCTGGAGGAGTTAGAGTTC and TAGAAAGATGGGGCAG-
GTGGTC, CAAAGAAGTTGTCTGGGGTGTGC and TTCATCCTCAGT-
CAAGGGCATCGG. Primers used to estimate relative levels of LTP-a-
ssociated splice isoforms: TTTCCCAGAGACTTGTCCCTACG and GG-
CTTTTGTGGCTATCCTGATG (primers b-c), AACTCCGCCCCTATGT-
CAAGTG and TACACGACTCCCTGCATGTTCG (primers a-d). Primers
used to amplify full-length Pde10A3 were TTAAAGGTGGGAGCAAA-
GGCCC and ATCAGTCATCGACCTTCCTGGTCG, those used to
amplify full-length Pde10A11 were ATGTCGAAGAAGCGCAAAGC-
CCTC and ATCAGTCATCGACCTTCCTGGTCG.
cAMP and cGMP Measurements—Sequence-verified full-length rat
Pde10A3 and Pde10A11 were cloned into pcDNA3.1 (Invitrogen). Cos7
cells, grown on 6-well plates, were transfected with the Pde10A con-
structs or peYFP-C1 (Clontech) using DEAE dextran (45). Prior to
cAMP and cGMP measurement, transfection efficiency was monitored
as the percentage of cells that expressed eYFP monitored with a fluo-
rescent microscope. In our hands, this method routinely transfects
70–80% of cells in culture. 18–24 h following transfection, cAMP and
cGMP measurements were performed (cAMP or cGMP enzyme immu-
noassay biotrack system, Amersham Biosciences) according to instruc-
tions from the manufacturer. Levels were expressed relative to the total
amount of protein in each sample. Protein concentrations were meas-
ured using a BCA protein assay kit (Pierce) according to the instruc-
tions from the manufacturer. cGMP experiments are averages of five
values obtained in two independent experiments, cAMP experiments
are averages of four values (four independent experiments) for each
construct.
RESULTS
Identification of LTP-associated Transcripts—Tetanic stim-
ulation of the perforant path in freely moving rats induced a
stable form of LTP, measured by the mean increase in the slope
of evoked EPSPs, that persisted at least 6 h without decrement
(Fig. 1A). Control rats receiving a similar number of stimuli at
low frequency did not display such increase in EPSP slope (CS
group; data not shown). Animals were sacrificed 1, 3, and 6 h
after tetanic stimulation, or 1 h after control stimulation, and
RNA was extracted from the dorsal half of the dentate gyrus
ipsilateral to the implanted electrodes. RNA extracted from the
dorsal half of the dentate gyrus from a group of naive animals
served as an additional control (naive group). We next per-
formed differential mRNA display (1) using the Hieroglyph
mRNA profile kit (Genomyx) to screen for LTP-modulated tran-
scripts (Fig. 1B). Candidate LTP-modulated transcripts were
then subjected to a second screening round on independently
generated brains using in situ hybridization. In situ hybridiza-
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FIG. 1. Differential display of gene expression in LTP. A, tetanization of the perforant pathway in freely moving adult rats results in a
stable form of LTP that persisted at least 6 h without decrement. Control rats not receiving high frequency stimulation did not display such
increase in slope EPSP (data not shown). B, RNA extracted from the dorsal half of the stimulated dentate gyrus was used to screen for
LTP-regulated transcripts. Differential display analysis yielded many candidate differentially expressed clones (see labeled examples). In situ
hybridization confirmed the LTP-associated expression of five clones that represent two independent transcripts (cl13/19/90 and cl95/96). These
transcripts are up-regulated 1 h after the induction of LTP. C, highest basal expression levels of these clones is found in the cerebellum as
determined by in situ hybridization on horizontal (hor) sections derived from adult rat brain (examples obtained with probes directed against
cl13/19/90; cl95/96 has an identical spatial distribution; data not shown). Other brain regions with detectable expression levels of cl13/19/90 and
cl95/96 include the dentate gyrus, areas CA1 and CA3 of the hippocampal formation, and olfactory bulb. cor, coronal section of adult rat brain; ctr,
control.
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tion was performed using radiolabeled 45-mer oligonucleotides
complementary to the sequence of differentially regulated tran-
scripts. From this secondary screen we confirmed differential
expression of five clones: cl13, cl19, cl90, cl95, and cl96. Se-
quence identity between these clones indicated that they rep-
resent two independent transcripts (Fig. 1B): cl13/19/90 and
cl95/96. Both clones were strongly up-regulated 1 h after the
induction of LTP and returned to pre-tetanus levels 3 h follow-
ing tetanization (n  4 for each time point). No up-regulation
was observed in the dentate gyrus of animals receiving a pseu-
do-tetanus or those in which the tetanus was delivered in the
presence of the NMDA receptor antagonist 3((R)-carboxyp-
iperazin-4-yl)-propyl-1-phosphonic acid (10 mg/kg, n  4 for
each condition, data not shown).
The two transcripts exhibit a similar spatial distribution as
determined by in situ hybridization. In the adult rat, under
basal, non-tetanized conditions, cl95/96 and cl13/19/90 are ex-
pressed at highest levels in the cerebellum. Other regions with
detectable expression levels include the olfactory bulb, the den-
tate gyrus, areas CA1–CA3 of the hippocampal formation, and
cortex (Fig. 1C). In addition to their similar spatial distribu-
tion, both cl13/19/90 and cl95/96 are expressed at similar low
levels. Expression levels can be estimated by in situ hybridiza-
tion as the time required to develop a signal on autoradio-
graphic film. Approximately 3 months of exposure was required
for cl13/19/90 and cl95/96 to reach quantifiable signal intensi-
ties on autoradiographic film compared with 4 days of expo-
sure for Zif268 (see also Ref. 29), indicating 20–30-fold lower
expression levels.
cl13/19/90 and cl95/96 Both Lie within an Intron of the
Pde10A Gene—As our differential display screen identified
only a partial cDNA sequence, we set out to determine the
nature of the complete transcript of cl13/19/90 and cl95/96.
Cl13/19/90 and cl95/96 appear to lie in a non-coding part of the
full-length transcript as they do not contain any large open
reading frames. Interestingly, Northern blot analysis failed to
identify a full-length cl13/19/90 or cl95/96 transcript (results
not shown) whereas other mRNAs using the same blots were
readily detectable (see, e.g., Ref. 46). The size of the full-length
mRNA of cl13/19/90 or cl95/96 therefore remained elusive. We
next compared the cDNA sequence of cl13/19/90 and cl95/96 to
the public domain sequence data bases. To our surprise we did
not detect significant homology to (i) the non-redundant data
base that contains mRNA sequence, (ii) the data base of ex-
pressed sequence tags, or (iii) the data bases of the completed
human or mouse genome. The lack of homology of cl13/19/90
and cl95/96 to these data bases therefore did not help deter-
mine the nature of their complete mRNA transcript.
The cDNA sequence of cl13/19/90 and cl95/96 did, however,
show a clear homology when compared with the draft genome
sequence of the rat, the species used for our differential display
screen. Interestingly, both cl13/19/90 and cl95/96 lie in close
proximity (80 kb) to each other on chromosome 1. Neither clone
contain introns themselves as they match contiguously on the
genome. Although no confirmed transcripts are present in close
(40 kb) vicinity, both clones are situated within the same
large (200 kb) intron of the Pde10A gene (Fig. 2). The absence
of any information regarding the identity of the full-length
transcript of cl13/19/90 and cl95/96 therefore led us to hypoth-
esize these clones may be part of the gene in which they are
localized. In theory, cl13/19/90 and cl95/96 could be part of the
Pde10A gene either as part of its primary transcript or as a
novel splice variant. However, it is also possible cl13/19/90 and
cl95/96 are not part of the Pde10A gene at all. Our next exper-
iments were performed to discriminate between these options.
We first hypothesized that, if cl13/19/90 and cl95/96 are part
of the Pde10A primary transcript, we should be able to detect
other regions of the primary transcript. We therefore per-
formed RT-PCR on intronic regions of the Pde10A gene indi-
cated by an asterisk in Fig. 2 using DNase-treated, reverse
transcribed RNA derived from adult rat hippocampus and cer-
ebellum. Interestingly, all RT-PCR reactions confirmed the
presence of intronic Pde10A sequence (examples are shown in
Fig. 3), with the notable exception of a reaction performed
outside the Pde10A gene (primers o-p, Figs. 2 and 3). The
amplified fragments include introns that lie 3 to the common
intron that encompasses cl13/19/90 and cl95/96. The PCR prod-
ucts were not the result of amplification of genomic DNA, as
they were only observed using reverse transcribed RNA and
not in control reactions using non-reverse transcribed RNA.
Identical results were obtained using RT-PCR on cDNA de-
rived from adult rat cerebellum (results not shown). Because
amplification of other intronic regions of the Pde10A gene may
not have been detectable if cl13/19/90 and cl95/96 encode either
a novel Pde10A splice variant or are part of a separate gene,
our results favor the hypothesis that cl13/19/90 and cl95/96 are
part of the Pde10A primary transcript.
We next hypothesized that, if cl13/19/90 and cl95/96 are part
of the Pde10A gene, the gene itself should show an identical
expression pattern and LTP-dependent modulation. We there-
fore performed in situ hybridization on the Pde10A gene using
sections of rat brains in which LTP was induced and followed
for 1 h. Because the Pde10A gene is subjected to alternative
splicing (41, 42, 47, 48), we performed in situ hybridization on
several of these variants (oligonucleotide probes YC–YG, loca-
tion indicated in Fig. 2). Because exon Ib (see Fig. 6) is part of
both Pde10A3 and Pde10A6 splice variants, in situ probe YF
cannot distinguish between these isoforms. Similarly, exon II is
part of both Pde10A5 and Pde10A11 splice variants and there-
fore in situ probe YE cannot distinguish between these two
isoforms.
Indeed, in situ hybridization confirmed the LTP-associated
up-regulation of several Pde10A splice isoforms (Fig. 4);
Pde10A3/A6 and A5/A11 are both up-regulated following LTP
FIG. 2. Genomic organization of the rat Pde10A gene. Depicted are exons (not to scale) of various Pde10A splice variants on a 500-kb
region of rat chromosome 1. *, sites at which RT-PCR experiments were performed. All RT-PCR reactions were designed to amplify intronic
sequence. g-h, i-j, k-l, m-n, and o-p are RT-PCR primer pairs as used in Fig. 3. YC, YD, YE, YF, and WS are sites probed in the in situ hybridization
experiments displayed in Figs. 4 and 5. Scale bar indicates position of exons relative to the last exon of Pde10A (kb).
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induction (probes YE and YF, respectively, indicated in Fig. 2)
whereas Pde10A2 and A4 are not (probes YG and YD). The
LTP-associated expression was observed in the dentate gyrus
ipsilateral to the side of stimulation (n  4). No up-regulation
was found in the contralateral hippocampus (n  4) or in
animals in which the electrodes were implanted without elec-
trical stimulation (n  2, data not shown). A detailed analysis
of all LTP-associated Pde10A splice variants is given in Fig. 6.
A region common to all splice variants (probe YC) shows a
modest LTP-associated up-regulation, which can be expected if
it reflects expression of both LTP-associated and non-activity-
dependent splice variants. To confirm these observations, we
performed similar experiments on tissue obtained 1 h after the
induction of a maximal seizure (see “Experimental Proce-
dures”). Seizures have been reported to cause a stronger tran-
scriptional response than LTP (20) and have been used to
identify genes modulated by electrical activity (20, 21, 23, 49).
Indeed, in situ hybridization confirmed that not only cl13/19/90
and cl95/96 (results not shown), but also Pde10A3/6 and
Pde10A5/11 show seizure-associated up-regulation (Fig. 4, n 
3). Pde10A2 and Pde10A4 are not up-regulated following sei-
zure; if anything, there was a trend toward down-regulation.
Based on the short half-life of primary transcripts, the ex-
pression levels of a gene can be expected to be higher than that
of its primary transcript. Indeed, individual Pde10A splice
variants had signal intensities20-fold stronger than those for
cl13/19/90 and cl95/96, determined by the time required to
reach comparable signal intensities on autoradiographic film.
Our observations that (i) specific Pde10A splice variants are
up-regulated following LTP induction, (ii) these splice variants
show an identical spatial expression pattern compared with
cl13/19/90 and cl95/96, and (iii) expression levels of Pde10A
splice variants are markedly higher than those of cl13/19/90
and cl95/96 favor the hypothesis that cl13/19/90 and cl95/96 are
part of the Pde10A primary transcript.
If cl13/19/90 and cl95/96 are indeed part of the Pde10A
primary transcript, we hypothesized that an in situ hybridiza-
tion experiment directed at a random intronic sequence of the
Pde10A gene should give not only identical activity-associated
up-regulation but also similar levels of expression as cl13/19/90
and cl95/96. In situ hybridization performed against a random
intronic Pde10A sequence (probe WS, the location of which is
depicted in Fig. 2) indeed showed both seizure-associated up-
regulation and a very low level of expression (Fig. 5, n  3).
Similar to cl13/19/90 and cl95/96, probe WS required1-month
exposure time on autoradiographic film before expression was
detected. Our findings that probe WS (directed against an
arbitrary selected intronic sequence) and cl13/19/90 and
cl95/96 have similar expression levels argues against the pos-
sibility that cl13/19/90 and cl95/96 encode novel splice variants.
Characterization of LTP-associated Pde10A Splice Vari-
ants—Putative amino acid sequences have been described for
some of the LTP-associated Pde10A splice variants (Pde10A3,
Pde10A5, and Pde10A6) (41). The cDNA sequences of the splice
variants used for the design of oligonucleotide probes were
obtained by means of data base comparison to the reverse
translated predicted protein sequences. In the public domain
data bases, several transcripts were present that exhibit se-
quence identity to the Pde10A splice variants, Pde10A3,
Pde10A5, and Pde10A6 (41). These splice variants all share a
FIG. 3. RT-PCR performed on various intronic regions of the Pde10A gene amplified fragments of predicted length. We were unable
to amplify fragments in a region outside the Pde10A gene (o-p). These results suggest the primary transcript of Pde10A can be detected by RT-PCR.
PCR products were only observed using reverse transcribed RNA (cDNA); no product was detected when using non-reverse transcribed RNA (ctr).
This indicates the PCR products were not the result of amplification of genomic DNA. Identical results were obtained using RT-PCR on cDNA
derived from adult rat cerebellum (data not shown).
FIG. 4. LTP-associated up-regula-
tion of specific Pde10A splice vari-
ants. In situ hybridization directed
against individual Pde10A splice variants
demonstrates Pde10A3/A6 and Pde10A5/
A11 are up-regulated following the induc-
tion of LTP (n  4) and maximal seizures
(n  3, probes YE and YF, respectively;
Fig. 2); splice variants Pde10A2 and
Pde10A4 are not (probes YG and YD). A
region common to all splice variants
(probe YC) shows a modest LTP-associ-
ated up-regulation that can be expected if
it reflects expression of both LTP-associ-
ated and non-activity-dependent splice
variants. ctr, control; sz, seizure.
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common 5 region, which indicates they may be derived from a
single promotor. To estimate the relative levels of individual
splice variants, we performed RT-PCR on RNA isolated from
adult rat hippocampus, cerebellum, cortex, and olfactory bulb
(all regions expressing cl13/19/90 and cl95/96). RT-PCR using
primers a–d yielded two distinct bands of approximately 520
and 390 bp, the expected fragment size for Pde10A3 and
Pde10A6, respectively (Fig. 6). Of the two, Pde10A3 (Gen-
BankTM accession no. AY462095) appears to be most abundant.
RT-PCR using primers b-c also yielded two distinct bands of
approx. 840 and 720 bp (Fig. 6). Again, the largest and most
abundant fragment corresponded to the expected size for
Pde10A3. Sequence analysis identified the lower fragment as a
novel splice variant, which we coined Pde10A11 (GenBankTM
accession no. AY462091). Additional sequence analysis on all
products generated by the RT-PCR reaction revealed several
additional novel Pde10A splice variants, Pde10A12–A14 (ac-
cession nos. AY462092, AY462093, and AY462094). These frag-
ments, although detectable by RT-PCR, are clearly not as
abundant as Pde10A3, -A6, or -A11. In Fig. 6 we present a
model of splicing of the first four exons of the LTP-associated
splice variants of the Pde10A gene. The relative levels of indi-
vidual splice variants were identical in the different brain
regions examined.
The large number of splice variants give rise to several
protein products of which Pde10A3, Pde10A5, Pde10A11, and
Pde10A12 have unique amino acid sequences. Pde10A6,
Pde10A13, and Pde10A14 do not possess such unique N-termi-
nal amino acid sequence, as they have translational start sites
downstream of exon IV (in a region common to all Pde10A
isoforms). A weak splice donor sequence was found in exon Ib;
splicing may occur at various sites at the 3 end of this exon
(sequence TTGTACTGGAGeˆGATACTTTGGCGGeˆCAGeˆ, with
splice sites indicated with eˆ). The putative protein sequence of
splice variants using this exon is not affected because it is part
of the 5 UTR.
The splice variants modulated by LTP all had exons I and/or
II as upstream exons, suggesting that these transcripts shared
a common promotor. Our observations that the relative levels
of Pde10A3, Pde10A6, and Pde10A11 are similar between the
various brain regions examined (as determined by RT-PCR)
and that the relative levels of Pde10A3/A6 and Pde10A5/A11
splice variants remain similar following LTP induction (as
determined by in situ hybridization, Fig. 4) argues against the
possibility of regulated splicing between the LTP-associated
splice variants.
Pde10A3 Expression Reduces Elevations in cGMP Concentra-
tions—Because Pde10A is likely to function as a cyclic nucleo-
tide phosphodiesterase, we examined the effect of Pde10A ex-
pression on cellular cAMP and cGMP levels. Full-length rat
Pde10A3 (the most abundant LTP-associated Pde10A splice
isoform, see Fig. 6) was transiently transfected into Cos7 cells.
cGMP content was measured using a cGMP enzyme immuno-
assay, and expressed relative to the total amount of protein in
each well. As can be seen in Fig. 7, expression of Pde10A3 did
not affect basal levels of cGMP as compared with control
(eYFP)-transfected cells. When Cos7 cells were stimulated for
10 min with 107 M atrial natriuretic peptide (ANP), a stimulus
that induces cGMP production (50, 51) control (eYFP)-trans-
fected cells responded with a 2-fold increase in cGMP levels
(28.1  2.4 and 57.7  5.2 fg of cGMP/g of protein, p  0.001).
In contrast, Pde10A3-transfected Cos7 cells did not respond to
ANP with an increase in cGMP levels (26.9  5.5 and 32.2 
9.6 fg of cGMP/g of protein, p 0.05 ANP-stimulated Cos7 cells
eYFP versus Pde10A3). These results suggest that Pde10A3
functions as a cGMP phosphodiesterase but only on elevated
cGMP levels. Because Pde10A can hydrolyze both cAMP and
cGMP (40, 42, 43), we also measured effects of Pde10A expres-
sion on cAMP levels. Full-length rat Pde10A3 or Pde10A11 was
transiently transfected into Cos7 cells. As can be seen in Fig. 7,
expression of the LTP-associated Pde10A isoforms Pde10A3 or
Pde10A11 affected neither basal nor forskolin-stimulated
cAMP levels compared with control (eYFP)-transfected cells.
No difference was observed using either Pde10A3 or Pde10A11
(n  4 for each); data are therefore combined in Fig. 7. These
results suggest that, although Pde10A can hydrolyze cAMP in
vitro, in intact cells it does not affect cAMP levels. Alterna-
tively, the forskolin-stimulated cAMP levels may not be suffi-
ciently high to reach the Km for cAMP of Pde10A3.
DISCUSSION
We have employed differential display of expressed mRNAs
(1) to identify genes induced by LTP in the hippocampus of
awake rats. This study identified 150 candidate-regulated
genes that were subjected to a second screening round using in
situ hybridization. We confirmed the differential expression of
five LTP-regulated clones representing two independent tran-
scripts, cl13/19/90 and cl95/96.
Neither cl13/19/90 nor cl95/96 showed significant sequence
homology to any known transcript (mRNA or expressed se-
quence tag) in mouse, rat, or human data bases, or to any
genomic sequence in mice or humans. The two clones did,
however, show sequence identity to two genomic sequences in
the rat, both localized to the same intron of the Pde10A gene.
Our evidence suggests that cl13/19/90 and cl95/96 are part of
the Pde10A primary transcript rather than parts of a distinct
uncharacterized gene within the intron because: (i) randomly
selected primers can detect all introns examined of the Pde10A
primary transcript using RT-PCR and in situ hybridization; (ii)
Pde10A splice variants (Pde10A5/A11 and Pde10A3/A6) are
also up-regulated following the induction of LTP (the probes we
used did not allow us to distinguish between A5 and All, and
between A3 and A6; however, we can infer that at least two of
the splice variants A3, A5, A6, and A11 were up-regulated); (iii)
cl13/19/90 and cl95/96 have an identical expression pattern to
the LTP-associated splice variants of Pde10A; (iv) expression
levels of cl13/19/90 and cl95/96 are markedly lower than that of
Pde10A mRNA as expected from the relatively short half-life of
the primary transcript, and (v), other regions of the primary
transcript show identical LTP-associated up-regulation and
expression levels. Furthermore, cl13/19/90 and cl95/96 show
other features that can be expected if they are part of a primary
transcript: (i) Northern blot analysis using cl13/19/90 or cl95/96
failed to identify any full-length transcript, (ii) cl13/19/90 and
cl95/96 do not contain a large open reading frame, and (iii)
cl13/19/90 and cl95/96 are themselves intronless.
Our experiments highlight the potential use of differential
display to identify changes in expression levels of RNA species
FIG. 5. In situ hybridization performed against a random in-
tronic Pde10A sequence (probe WS, see location in Fig. 2) show-
ing activity-associated up-regulation. As with cl13/19/90 and cl95/
96, probe WS required 1 month of exposure time on autoradiographic
film before expression was detected. Because the expression levels of a
primary transcript is likely to be lower than that of its mRNA, this
finding favors the possibility that cl13/19/90 and cl95/96 are part of the
Pde10A primary transcript and do not encode novel splice variants. Ctr,
control; SZ, seizure.
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other than mRNA. Why our differential display screen identi-
fied Pde10A primary transcript in preference to its mRNA
remains to be determined. It is possible that the nature of the
experiment (i.e. number of amplification cycles) favored the
detection of low abundant transcripts. Alternatively, large in-
trons have a relatively long half-life because introns have to be
transcribed in full before they can be spliced out. The half-life
of an intron is therefore determined by its length and by the
rate of RNA polymerase II transcription. The latter has been
estimated to range from 1–2.5 kb/min (28, 55), suggesting
that the 200-kb Pde10A intron in which cl13/19/90 and cl95/96
are situated requires at least 80 min to be transcribed in full.
Significantly, our results indicate that levels of the primary
transcript can be used to study the activity of a gene.
Although we provide evidence that cl13/19/90 and cl95/96 are
part of the Pde10A primary transcript, we cannot exclude the
possibility that they are part of a large intron retained in the
mRNA. Intron retention can form a mechanism to generate
alternative splice variants and results in the presence of in-
tronic sequence within mRNA (see, e.g., Refs. 52–54). It should
be noted that all examined introns can readily be detected by
RT-PCR (see Figs. 2 and 3), an observation that argues against
retention of a specific intron. However, because intron reten-
tion may be a regulated process (53), it remains possible that
cl13/19/90 and cl95/96 are part of an intron that is retained in
an activity-dependent manner. Such a transcript would form a
minority of mRNA species, as the expression levels of cl13/
19/90 and cl95/96 are markedly lower than those of predicted
exons. It should also be noted that, for Pde10A3, the transla-
tional start site lies downstream of the putatively retained
intron and may not affect the Pde10A protein product.
Because our screen identified clones upstream from the
poly(A) tail, it follows that the primers used to generate cDNA
hybridized to an alternative sequence. There are several
poly(A) stretches within the Pde10A primary transcript that
can form priming sites for reverse transcription. This priming
site forms the 3 end of our differentially expressed clones, and
was identified as agctcCGAAAAAAAAAAAAaagaaaaa (5 to 3)
for cl13, cl19, and cl90, and gaccaaTGAAAAAAAAggAggccg for
FIG. 6. Relative abundance of LTP-associated splice variants. A, splicing of the first four exons of the LTP-associated splice variants of the
Pde10A gene (top left). All LTP-associated splice variants share a common 5 exon, suggesting they may be derived from a common promotor. Not
depicted are Pde10A13 and Pde10A14; they are derived by combining exons Ia-Ib-IV-V- (skipping exons II and III) and Ia-Ib-VIII-IX- (skipping
exons II-VII), respectively. Arrows in exons II and III indicate translational start sites. B, RT-PCR was performed to estimate the relative levels
of individual splice variants. RT-PCR primers a–d (position indicated in A) yielded two distinct bands of approximately 520 and 390 bp, the
expected fragment size for Pde10A3 and Pde10A6, respectively. Of the two, Pde10A3 appears to be most abundant. RT-PCR using primers b and
c also yielded two distinct bands of approximately 840 and 720 bp. Again, the largest and most abundant fragment corresponded to the expected
size for Pde10A3. Sequence analysis identified the lower fragment as a novel splice variant, we coined Pde10A11. The relative levels of individual
splice variants were identical in the different brain regions examined. C, the predicted unique amino acid sequence of LTP-regulated splice
variants. LTDEK represents start of the protein sequence present in all (regulated and non-regulated) Pde10A isoforms. The translation initiation
site for Pde10A5, -A11, and -A12 is located in exon II; for Pde10A3 it is located in exon III.
FIG. 7. Regulation of cyclic nucleotides by Pde10A3. Left: Tran-
sient transfection of Pde10A3 into Cos7 cells reduces the ANP-induced
cGMP elevation. ANP (107 M) was applied for 10 min. Basal cGMP
levels (ns) were similar in Pde10A3-transfected and eYFP-transfected
cells. However, Pde10A3-transfected Cos7 cells did not respond to ANP
with an increase in cGMP levels, whereas control cells responded with
a2-fold increase in cGMP levels (p 0.001, stimulated cells compared
with non-stimulated cells; p  0.05, stimulated control cells compared
with stimulated, Pde10A3-transfected cells). Right, transient expres-
sion of the LTP-associated Pde10A isoforms Pde10A3 or Pde10A11
neither affected basal nor forskolin-stimulated cAMP levels compared
with eYFP control-transfected cells. Forskolin (fors, 105 M) was applied
for 30 min. Forskolin induced an increase in cellular cAMP levels both
in eYFP- and Pde10A3/A11-transfected cells (p  0.05 for both, com-
pared with corresponding non-stimulated cells). No difference was ob-
served using either Pde10A3 or Pde10A11 (n  4 for each), and data
have therefore been combined.
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cl95 and cl96 (caps denote nucleotides complementary to the
RT-primer). These sequences are complementary to the last 14
(cl13 and cl19) and 10 nucleotides (cl95 and cl96) of the RT
primer. The priming site for cl90 has one mismatch with the
genomic sequence at the penultimate base. These short
genomic poly(A) stretches, when part of the primary tran-
script, are therefore apparently sufficient to serve as priming
sites for reverse transcription.
The Pde10A gene is a member of the phosphodiesterase gene
family, which contains over 11 subfamilies (PDE1–11), encoded
by at least 19 different genes (56, 57). Of these, PDE4 has also
been shown to be associated with electrical stimulation (26, 58).
Pde10A can hydrolyze both cAMP and cGMP (40, 42, 43),
although the enzyme is suggested to have a higher specific
activity for cGMP (40). Our data confirm the hypothesis that
Pde10A functions as a cGMP phosphodiesterase; our data also
show that in Cos7 cells Pde10A3 only affects stimulated in-
creases in cGMP concentrations, whereas it does not reduce
basal cGMP levels. These findings are likely to be related to the
relatively low affinity of Pde10A for cGMP. We also found that
neither Pde10A3 nor Pde10A11 affects cellular cAMP levels.
Although our data suggest Pde10A does not function as a cAMP
phosphodiesterase, it remains possible that the forskolin-stim-
ulated cAMP levels achieved in these experiments were not
sufficiently high to reach the Km for cAMP. It has been postu-
lated that cAMP inhibits cGMP hydrolysis (43). Pde10A may
therefore function as a cAMP-inhibited cGMP phosphodiester-
ase (40, 43), and it is possible therefore that cGMP signaling
will be affected in cells with an increased expression of Pde10A.
One postulated function of cGMP is to act in presynaptic
terminals as a downstream effector of the retrograde messen-
ger NO via activation of a soluble guanylate cyclase (59). Down-
stream effectors of cGMP include cGMP-dependent protein ki-
nase I and II, both of which are expressed in the hippocampus
(60, 61). Several studies have provided evidence for a role of the
NO-cGMP pathway in synaptic plasticity: (i) inhibitors of ni-
tric-oxide synthase, guanylyl cyclase or cGKs can block the
induction of LTP (62–67); (ii) exogenous NO paired with a brief
tetanus can generate a stable NMDA receptor-independent
potentiation (Refs. 66 and 68, but see Ref. 69); (iii) a hippocam-
pal specific deletion of cGK-I diminished LTP in adult mice
(70); and (iv) brief perfusion of 8-br-cGMP before weak tetanic
stimulation produces long lasting potentiation (65, 66). To-
gether these data suggest that stimulation of the NO-cGMP
pathway facilitates synaptic plasticity, whereas inhibition of
this pathway depresses it. Our finding that the cGMP phos-
phodiesterase Pde10A gene is up-regulated following the in-
duction of LTP is likely to act as a damper on further episodes
of LTP. Interestingly, it was recently reported that LTP is
associated with a prolonged reduction in cGMP levels (71), and
it is tempting to speculate that this reduction is linked to our
finding of an up-regulation of Pde10A. The post-synaptic up-
regulation of Pde10A described here argues for a post-synaptic
role for the cGMP pathway. Although many reports have con-
centrated on the functions of cGMP at the presynaptic termi-
nal, some postsynaptic effects of the NO-cGMP pathway have
also been described (66, 67, 72).
The Pde10A gene is subjective to alternative splicing (41, 42,
47), and we report the cloning of four novel splice variants
Pde10A11–Pde10A14. Although some splice variants may be
regulated by protein kinases (47), the function of most splice
variants remain to be determined. Apart from a specialized
function for each splice variant, it is also possible that the
LTP-associated splice isoforms do not possess unique features;
the electrical responsiveness of the promotor is then used to
generate more protein product. The LTP-associated splice iso-
forms, Pde10A3, Pde10A6, and Pde10A11, can be expected to
exhibit phosphodiesterase activity, as they all contain the di-
esterase domain. Two GAF domains (for cGMP-binding phos-
phodiesterases, the cynobacterial Anabaena adenylyl cyclase,
and the Escherichia coli transcriptional regulator fhlA) (73),
domains that bind cGMP, are also present in the LTP-associ-
ated splice variants.
Our results indicate that some splice variants of Pde10A are
up-regulated following the induction of LTP, whereas others
(e.g. Pde10A2 and Pde10A4) are not. Because all LTP-associ-
ated Pde10A splice variants share a common 5 exon, it is likely
that all variants are derived from a common, activity-regulated
promotor. Our observations that relative levels of individual
splice variants remains similar in different brain regions (as
determined by RT-PCR) and the relative levels of Pde10A5/A11
and Pde10A3/A6 splice variants remain similar following LTP
induction (as determined by in situ hybridization; Fig. 1) ar-
gues against the possibility of regulated splicing between LTP-
associated Pde10A splice variants.
In summary, using differential display of expressed mRNAs,
we have identified two independent transcripts, cl13/19/90 and
cl95/96, that are up-regulated following the induction of LTP.
We provide evidence demonstrating that these clones are part
of the Pde10A primary transcript, suggesting that levels of the
primary transcript can be used to study the activity of a gene.
Our results indicate that differential display, although primar-
ily aimed to identify changes in expression levels of mRNA, can
be used to identify differential expression of other RNA species.
Because we and others show that Pde10A encodes a cGMP
phosphodiesterase (40–43), our results argue for a role of the
cGMP/cGK pathway in long term synaptic plasticity.
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